Pain Therapeutics Files Form 8-K Regarding Correspondence From Pfizer, Inc.

AUSTIN, Texas, May 10, 2013 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that yesterday it received correspondence from Pfizer, Inc. (NYSE:PFE).

This correspondence is available at:

The company furnished the correspondence with the Securities and Exchange Commission pursuant to the submission of a Current Report on Form 8-K.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel drugs. The FDA has not approved any of our drug candidates for commercial sale. For more information, please visit
CONTACT: For More Information Contact:                  Peter S. Roddy         Vice President and Chief Financial Officer         Pain Therapeutics, Inc.         (512) 501-2450